# CNDO-109-AANK for AML in First Complete Remission (CR1)

> **NCT01520558** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Coronado Biosciences, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CNDO-109-AANK Cells

## Key facts

- **NCT ID:** NCT01520558
- **Lead sponsor:** Coronado Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2016-03
- **Final completion:** 2018-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520558, "CNDO-109-AANK for AML in First Complete Remission (CR1)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01520558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*